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ABSTRACT
Dabigatran is an oral direct thrombin inhibitor (DTI)
licensed for stroke prevention in atrial ﬁbrillation and
likely to be soon approved in Europe for treatment of
venous thrombosis. Predictable pharmacokinetics and
a reduced risk of intracranial haemorrhage do not
negate the potential risk of haemorrhage. Unlike
warfarin, there is no reversal agent and measurement of
the anticoagulant effect is not ‘routine’. The prothrombin
time/international normalised ratio response to
dabigatran is inconsistent and should not be measured
when assessing a patient who is bleeding or needs
emergency surgery. The activated partial thromboplastin
time (APTT) provides a qualitative measurement of the
anticoagulant effect of dabigatran. Knowledge of the
time of last dose is important for interpretation of the
APTT. Commercially available DTI assays provide a
quantitative measurement of active dabigatran
concentration in the plasma. If a patient receiving
dabigatran presents with bleeding: omit/delay next dose
of dabigatran; measure APTT and thrombin time
(consider DTI assay if available); administer activated
charcoal, with sorbitol, if within 2 h of dabigatran
ingestion; give tranexamic acid (1 g intravenously if
signiﬁcant bleeding); maintain renal perfusion and urine
output to aid dabigatran excretion. Dabigatran exhibits
low protein binding and may be removed by dialysis.
Supportive care should form the mainstay of treatment.
If bleeding is life/limb threatening, consider an additional
haemostatic agent. There is currently no evidence to
support the choice of one haemostatic agent (FEIBA,
recombinant factor VIIa, prothrombin complex
concentrates) over another. Choice will depend on access
to and experience with available haemostatic agent(s).
Dabigatran etexilate is an oral direct thrombin
inhibitor (DTI), which is rapidly absorbed after oral
administration, reaching a peak plasma concentra-
tion and maximal anticoagulant effect within
2–3 h.1 Dabigatran displays linear pharmacokinet-
ics, over a wide range of doses, which allows it to
be given in a ﬁxed-dose regimen without the need
for routine coagulation monitoring.2 3 Although
the risk of spontaneous intracranial haemorrhage
(ICH) is reduced,4 patients receiving this drug are
fully anticoagulated and are at risk of bleeding,
particularly in association with trauma5 and surgery
and after the development of renal failure.6
The RE-LY Study2 compared two doses of dabi-
gatran (150 mg and 110 mg twice a day) with
dose-adjusted warfarin for stroke prevention in
atrial ﬁbrillation. The primary efﬁcacy outcome of
the study was stroke or systemic embolisation. The
150 mg dose of dabigatran was superior to warfarin
(1.11% vs 1.71%, relative risk (RR) 0.65 (95% CI
0.52 to 0.81) p<0.001). The primary safety
outcome was major bleeding events. The rate of
major bleeding was signiﬁcantly less in the dabiga-
tran 110 mg group compared with warfarin
(2.87% vs 3.57%, p=0.003, respectively), but was
similar to warfarin in the dabigatran 150 mg group
(3.32% vs 3.57%) per year with a RR of 0.93
(95% CI 0.81 to 1.07; p=0.32).
In England and Wales, The National Institute for
Health and Clinical Excellence,7 and in Scotland
the Scottish Medicines Consortium,8 have recently
recommended the anticoagulant, dabigatran, to be
considered as an option for the prevention of
stroke and systemic embolism in people with atrial
ﬁbrillation. As prescriptions for dabigatran increase,
clinicians will need to be prepared to deal with
complications such as bleeding (spontaneous and
trauma-related) as well as patients who require
semi-urgent or urgent surgery.
The recently published 9th American College of
Chest Physicians clinical practice guidelines9 state
that ‘there is insufﬁcient clinical experience to
ﬁrmly guide the management of major bleeding,
suspected overdose, urgently needed surgery, or
urgent invasive diagnostic or therapeutic proce-
dures in patients who are taking this new drug’.
These comments offer little solace or guidance to a
clinician faced with having to manage one of the
above described scenarios. This paper aims to
provide practical advice to clinicians on the labora-
tory investigation and acute management of
patients presenting while anticoagulated with
dabigatran.
COAGULATION ASSAYS: MEASURING THE
EFFECT OF DABIGATRAN
Prothrombin time /international normalised
ratio
Vitamin K antagonists, such as warfarin, reduce the
levels of the coagulation factors II, VII, IX and X.9
The prothrombin time (PT) is particularly sensitive
to a reduction in factor VII, and, as a result, treat-
ment with vitamin K antagonists results in pro-
longation of the PT. This is usually expressed as a
standardised ratio (the international normalised
ratio (INR)), which is used to monitor the thera-
peutic anticoagulant effect of warfarin.10
The PT/INR is insensitive to dabigatran at thera-
peutic levels.11 It may be prolonged by suprathera-
peutic levels of dabigatran, but the results will vary
widely between laboratories, because of variation in
the sensitivity of different reagents to the effect of
dabigatran.11 Neither a laboratory-based nor
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point-of-care PT/INR can be used to assess the anticoagulant
effect of dabigatran.
Activated partial thromboplastin time
The activated partial thromboplastin time (APTT) provides a
measure of the intrinsic (factors VIII, IX and XI) and common
(factors II, V, X and ﬁbrinogen) coagulation pathway. The APTT
can be used to monitor the anticoagulant effect of unfractio-
nated heparin.12 The APTT displays a curvilinear dose response
to increasing plasma concentrations of dabigatran11 and may be
used to demonstrate that a patient is anticoagulated with dabiga-
tran—for example, if a patient is bleeding or needs surgery.
However, it does not provide a quantitative measurement and
should not be used for routine monitoring.
In the stroke prevention trial,2 the APTT ratio was 1.4–2.3 in
patients receiving 150 mg twice a day, and 1.3–2.1 in those
receiving 110 mg twice a day, with a peak effect seen 2 h after
administration.13 Prolongation of the APTT is maintained for at
least 8–12 h, with a measurable effect still seen in some patients
after 24 h.1 If the APTT is prolonged by 2–3-fold at trough
(when the next dose is due), there is a higher risk of bleeding.14 15
Therefore, knowledge of the time of last dose is important for
interpretation of the APTT, particularly if an invasive procedure
is planned.
Thrombin time
The thrombin time (TT) provides a measurement of the conver-
sion of ﬁbrinogen into ﬁbrin (clot). The TT displays a linear time
response to increasing plasma concentrations of dabigatran.1 In
general, the TT does not form part of a ‘routine’ coagulation
proﬁle and may not be readily available in clinical practice. In
addition, the TT is exquisitely sensitive to the presence of dabiga-
tran, and samples may be unclottable at therapeutic levels,
making it unsuitable as a quantitative assay.14 15 Conversely, a
normal TT indicates an absence of dabigatran anticoagulant
effect and could therefore be used to exclude the drug as a cause
of haemorrhage.
DTI assay
The commercially available HEMOCLOT (HYPHEN BioMed,
France)16 DTI assay avoids the over-sensitivity displayed by
standard TT assays. The clotting time is directly related to the
concentration of active dabigatran in the patient’s plasma and
can be used to measure the anticoagulant activity of dabigatran.
A DTI assay may be of use in assessing patients presenting with
bleeding or in those that require an urgent invasive procedure
or surgery.
MANAGEMENT OF BLEEDING
There are currently no antidotes available for reversing the anti-
coagulant effect of dabigatran, although preclinical work is
underway to develop a neutralising, dabigatran-speciﬁc mono-
clonal antibody.17 If a patient presents with bleeding, dabigatran
therapy should be discontinued until appropriate investigations
are completed and the patient is stabilised (ﬁgure 1).18–20
Activated charcoal
Activated charcoal is a processed form of carbon with a large
porous surface area available to bind to oral drugs such as dabi-
gatran21 22 and reduce absorption from the gastrointestinal
tract. Binding to charcoal is reversible; sorbitol is often added
for its laxative effect to speed transit through the intestines.
Since dabigatran is rapidly absorbed after ingestion, activated
charcoal is likely to be of greatest beneﬁt within 2 h of inges-
tion. Clinicians should bear in mind that absorption of concomi-
tant oral medication will also be impaired by administration of
charcoal.
Figure 1 Management of bleeding patient anticoagulated with dabigatran.18–20 APTT, activated partial thromboplastin time; TT, thrombin time;
eGFR, estimated glomerular ﬁltration rate; CrCl, creatinine clearance; BP, blood pressure; i.v. intravenous; Hb, haemoglobin; Plt, platelet; CNS,
central nervous system; FEIBA, factor eight inhibitor bypassing activity; PCC, prothrombin complex concentrate; rFVIIa, recombinant factor VIIa.
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Tranexamic acid
Tranexamic acid inhibits ﬁbrinolysis by inhibiting the binding of
plasmin to ﬁbrin. Tranexamic acid has been shown to reduce
bleeding after tissue injury associated with surgery23 and after
trauma.24 Based on the results of more than 200 randomised
control trials, the efﬁcacy of anti-ﬁbrinolytic drugs does not
appear to be offset by serious side effects.23 In the event of
major bleeding with dabigatran, 1 g tranexamic acid should be
given intravenously.
General supportive measures
Maintaining renal perfusion and urine output can aid elimination
of dabigatran, 80% of which is excreted through the kidneys
unchanged.25 Mechanical methods to arrest bleeding, including
compression, tamponade, surgery and radiological intervention,
are essential components of managing bleeding events.
Since the half-life of dabigatran is short (12–17 h),1 15 it is
envisaged that the majority of bleeding episodes will be
managed by supportive methods alone. However, if bleeding
continues or is life threatening, then an additional haemostatic
agent should be considered. It must be remembered that there is
no speciﬁc antidote for dabigatran and there is no ideal haemo-
static agent for this indication.
Dialysis
Dabigatran exhibits low protein binding and therefore it may be
possible to remove it from the circulation by dialysis. The plasma
concentration of dabigatran can be reduced by 50–60% after 4 h
of dialysis.26 27 Unfortunately, emergency access to haemodialysis
may be limited, and the technical issues surrounding establishing
venous access in an anticoagulated patient means that this treat-
ment option may only be available to a few patients.
Haemostatic agents that may be of use in the management
of bleeding
Prothrombin complex concentrates
Prothrombin complex concentrates (PCCs) contain factors II
(prothrombin), VII, IX and X, which are the vitamin
K-dependent factors affected by warfarin therapy. Dabigatran
directly inhibits thrombin, and, although administration of a
PCC will not inﬂuence this effect, it may provide more substrate
(prothrombin) to increase thrombin generation, which is essen-
tial for the formation of a ﬁbrin blood clot.
A number of animal studies have found that the PCCs,
Beriplex28–30 and Octaplex,29 result in haemostasis and reversal
of blood loss after supratherapeutic doses of dabigatran. In a
murine ICH model, a PCC resulted in cessation of bleeding asso-
ciated with dabigatran. It also prevented haematoma expansion
and signiﬁcantly reduced mortality.30 In contrast, in a study of
human healthy volunteers, a PCC (Cofact) failed to normalise
the prolonged APTTor TT caused by dabigatran,31 although the
effect on bleeding was not assessed in this study. It is important
to note that, in the animal models where a clinical effect was
seen, there was no improvement in the laboratory tests.29 30 32
The inability to measure the effect of PCC administration by
laboratory tests may result in larger doses of PCC being given
than necessary, leading to the potential for thrombotic
complications.
FEIBA
FEIBA (which has Factor Eight Inhibitor Bypassing Activity) is
currently used as a haemostatic agent for patients with anti-
bodies to factor VIII. Activated factor X and prothrombin
appear to be the main components in FEIBA responsible for its
haemostatic action,33 and they enable the generation of throm-
bin, independently of factor VIII. As in the case of PCCs, this
thrombin may still be inhibited by dabigatran.
In a rat tail bleeding model, FEIBA signiﬁcantly reduced the
bleeding time associated with dabigatran.22 As with the PCC
studies, the APTT remained prolonged after FEIBA administra-
tion despite the reduction in bleeding time. There is a single
case report of the successful use of FEIBA in the management
of a life-threatening bleeding event associated with dabigatran.34
It is likely that the prothrombotic effect of FEIBA is greater
than that of PCCs because of the coagulation factors being acti-
vated and that, if used, much smaller doses will be required
than those used for treating patients with haemophilia.
Recombinant factor VIIa
Recombinant factor VIIa (rFVIIa) is another bypassing haemo-
static agent used for the management of haemophiliac patients
with inhibitors. It is able to directly activate factors IX and X
resulting in a burst of thrombin generation (and thus ﬁbrin clot
formation) independently of factor VIII.35 As with the other
haemostatic agents, the generation of thrombin may in part
overcome the effect of dabigatran.
rFVIIa has also been shown to reduce dabigatran-induced
bleeding in a rat tail bleeding model with partial normalisation
of the APTT.29 However, in contrast with PCCs, rFVIIa failed
to reduce haematoma expansion or have an impact on mortality
in a murine ICH model.30
Following anecdotal evidence, the off-label use of rFVIIa for
non-haemophiliac patients who are bleeding has gained some
favour in the past decade. However, there is concern that rFVIIa
is associated with an increased risk of thrombotic complications.
A review of 35 randomised control trials of the off-label use of
rFVIIa identiﬁed a signiﬁcant increase in the risk of arterial
events, particularly in the elderly.36
Surgery/invasive procedure
When a patient receiving dabigatran requires an elective invasive
procedure, the consequences of bleeding if anticoagulation is
continued, with the risk of thrombosis if it is omitted, need to
be considered. In addition, as dabigatran is predominantly elimi-
nated via the renal pathway, this will need to be taken into
account when deciding for how long to stop dabigatran before a
procedure (table 1).
For patients who require urgent surgery, discussion with the
patient’s surgeon and anaesthetist are of paramount importance
(ﬁgure 2). A baseline assessment of coagulation should be
Table 1 Discontinuation rules for dabigatran before invasive or
surgical procedure8 14 15
Stop dabigatran before elective surgery
Renal function
(CrCl (ml/min))
Estimated
half-life(h)
Major surgery or
high bleeding risk*
Non-major surgery
or standard risk†
>80 ∼13 48 h before 24 h before
>50 and <80 ∼15 48–72 h before 24–48 h before
>30 and <50 ∼18 96 h before 48–72 h before
*Examples of major surgery/high bleeding risk: cardiothoracic surgery, neurosurgery,
major abdominal or pelvic surgery, major orthopaedic surgery, insertion of cardiac
pacemaker/defibrillator.
†Examples of non-major surgery/standard risk: uncomplicated laparoscopic procedure,
cardiac catheterisation/ablation therapy.
CrCl, creatinine clearance.
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performed, including the APTT. A normal APTT suggests that
the bleeding risk is low. A prolonged APTT may reﬂect the pres-
ence of dabigatran11 or, particularly in the setting of trauma or
sepsis, a coagulopathy. A DTI assay, if available, could provide
additional information about the risk of bleeding.14
Prolongation of the APTT and/or a measurable therapeutic
dabigatran concentration in the patient’s plasma should prompt
a discussion as to the feasibility of delaying surgery. A delay of
24 h in a patient with normal renal function will allow the con-
centration of dabigatran in the plasma to fall by 75%. If urgent
surgery is required, particularly within a few hours of dabigatran
ingestion, an increased risk of bleeding is likely.
To support drug elimination from the kidneys, renal perfusion
and urine output must be maintained. If a patient has taken
Figure 2 Management of patient anticoagulated with dabigatran requiring urgent surgery. APTT, activated partial thromboplastin time; TT,
thrombin time; eGFR, estimated glomerular ﬁltration rate; CrCl, creatinine clearance; BP, blood pressure; i.v. intravenous; Hb, haemoglobin; Plt,
platelet; CNS, central nervous system; FEIBA, factor eight inhibitor bypassing activity; PCC, prothrombin complex concentrate; rFVIIa, recombinant
factor VIIa.
Figure 3 Management of patient after an overdose of dabigatran. APTT, activated partial thromboplastin time; TT, thrombin time; eGFR, estimated
glomerular ﬁltration rate; CrCl, creatinine clearance; BP, blood pressure; i.v. intravenous; Hb, haemoglobin; Plt, platelet; CNS, central nervous system.
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dabigatran in the preceding 2 h and there is no surgical or
anaesthetic contraindication, activated charcoal may be consid-
ered as an option to reduce dabigatran absorption.
Regional anaesthesia should be avoided in a patient who
requires surgery within 24–48 h of ingestion of a therapeutic
dose of dabigatran (even if the APTT/DTI are normal).37
A decision to perform regional anaesthesia, on the basis of the
risk of general anaesthesia, should be thoroughly discussed with
the patient/relatives.
If bleeding occurs, then supportive measures should be used,
with crystalloids, red blood cells, platelets and plasma (ﬁgure 2).
Additional haemostatic agents may be considered during or after
surgery if bleeding continues. There is currently no evidence to
support the preoperative administration of a haemostatic agent.
After surgery, the risk of bleeding associated with the proced-
ure should be measured against the risk of thrombosis associated
with withholding anticoagulation. A therapeutic dose of dabiga-
tran should be withheld for 24–72 h after surgery, according to
the patient’s individual risk of bleeding and thrombotic risk.
Routine thromboprophylaxis with a licensed anticoagulant may
be considered 6–8 h after the operation and continued until
dabigatran therapy is re-introduced.
Overdose
In the event of accidental or intentional overdose, a baseline
APTT and TT or DTI assay should be performed (ﬁgure 3). If
normal, they should be repeated after 2 h, since plasma levels of
dabigatran peak within 2 h of ingestion. If the time of ingestion is
known, a 12 h APTT trough measurement can be used as an indi-
cation of the patient’s risk of bleeding; a trough APTT >2–3 times
the upper limit of normal or a plasma concentration of >200 ng/
ml is likely to be associated with a higher risk of bleeding.14 15
Activated charcoal with sorbitol should be considered for all
patients with suspected dabigatran overdose. It is likely to be of
most beneﬁt administered within 2 h of ingestion. The patient
should be warned of the potential for black stools, and the
medical team should also be made aware, to avoid misdiagnosis
of melaena.
After an overdose, it may be possible to remove dabigatran
from the circulation by haemodialysis, which reduces the plasma
concentration of dabigatran by 50–60% within 4 h of
dialysis.26 27
CONCLUSION
Despite the undoubted advantages offered by the new oral
anticoagulants such as dabigatran, it would be naive of us to
think that we will not be faced at some point in the near future
with a patient anticoagulated with this new drug who requires
urgent surgery or treatment for bleeding. At present, there is
little published evidence to guide clinicians. Our review and
practical suggestions are aimed at ﬁlling that void until such
time that studies addressing these issues are published or an
antidote to dabigatran is marketed.
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